A FRAMEWORK FOR EVALUATION OF PHARMACEUTICAL INDUSTRY DEVELOPMENT IN DEVELOPING COUNTRIES: EVIDENCE FROM IRAN
Objectives: The pharmaceutical market is a complex market due to its complicated supply chain and the extent of government regulations in all
aspects of the trade lifecycle of drug development. Considering the importance of pharmaceuticals for society and the relevant trend of globalization, managing pharmaceutical industry effectively and efficiently is vital, particularly in developing countries. The present study determines the factors affecting the development of the Iranian pharmaceutical industry based on pharmaceutical mangersâ€™ point of view.
Methods: In this study, we assessed managersâ€™ perspective about the internal and external key factors affecting the development of pharmaceutical
industry. Finally, their perspective about the solutions for the development of pharmaceutical industry was assessed. Accordingly, a self-designed
questionnaire was sent to 65 managers at Tamin Pharmaceutical Investment Company, of which, 51 questionnaires were answered by the managers.
Result: Most managers believed generic scheme reflect negatively on the development of the pharmaceutical industry and that external factors have
a great impact on its improvement. They believe that branded generic transition along with supporting regulations, investment in Research and
Development, and joint venture with foreign companies will improve the pharmaceutical industry.
Conclusion: To sum up, for improving the pharmaceutical industry in the shortest time possible, improvement of technological capabilities and
investment in R&D should be considered.
Keywords: Pharmaceutical industry, Key factors, Generic scheme.
2. Danzon PM, Towse A. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int J Health Care Finance Econ 2003;3(3):183-205.
3. Competitiveness of the EU Market and Industry for Pharmaceuticals. European Commission: Welfare Implications of Regulation; 2011.
4. Blau G, Mehta B, Bose S, Pekny J, Sinclair G, Keunker K, et al. Risk management in the development of new products in highly regulated industries. Comput Chem Eng 2000;24(2):659-64.
5. Holmer AF. The pharmaceutical industry â€“ to whom is it accountable? N Engl J Med 2000;343(19):1415.
6. Commission E. Communication from the Commissionâ€”Executive Summary of the Pharmaceutical Sector Inquiry Report. Reference EU Commission Report; 2009. p. 8.
7. Fischer MA, Avorn J. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Serv Res 2003;38(4):1051-63.
8. Hogerzeil HV, Mirza Z. The world Medicines Situation 2011: Access to Essential Medicines as Part of the Right to Health. Geneva: World Health Organization (WHO); 2011.
9. Basmanji K. Pharmaceuticals in Iran: An overview. History of Contemporary Medicine in Iran. Arch Iran Med 2004;7(2):158-64.
10. Mehralian G, Rasekh HR, Akhavan P, Sadeh MR. The Impact of intellectual capital efficiency on market value: An Empirical study from Iranian pharmaceutical companies. Iran J Pharm Res 2012;11(1):195-207.
11. Cheraghali AM. Iran pharmaceutical market. Iran J Pharml Res 2006;5(1):1-7.
12. Iran National Drug Policy (NDP) revision; 2004.
13. Mehralian G, Gatari AR, Morakabati M, Vatanpour H. Developing a suitable model for supplier selection based on supply chain risks: An empirical study from Iranian pharmaceutical companies. Iran J Pharm Res 2012;11(1):209-19.
14. Iran Pharmaceutical & Healthcare Report; 2004.
15. Davari M, Walley T, Haycox A. Pharmaceutical policy and market in Iran: Past experiences and future challenges. J Pharm Health Serv Res 2011;2(1):47-52.
16. Iran pharmaceutical & Healthcare Report. Business Monitor International; 2012.
17. Tantash M. Middle east generics, challenges and opportunity, journal of generic medicines. Journal of generic medicines. Bus J Generic Med Sect 2012;9(1):13-20.
18. Food & Drug regulation. Food & Drug Organisation; 2010.
19. Annual Report. Food & Drug Report; 2012. Available from: http://www.fdo.ir.\. [Last cited on 2013 Nov 4].
20. Force PICT. Competitiveness and Performance Indicators. London: PICTF; 2005.
21. Michels D, Jonnard A, Bretscher C, Summers J, Wanser S, Flynn J. Review of Global Competitiveness in the Pharmaceutical Industry. Washington, DC: US International Trade Commission Staff Research Study No.; 1999. p. 25.
22. Available from: http://www.tpico.ir. [Last cited on 2013 Nov 4].
23. Bagchi-Sen S. Strategic considerations for innovation and commercialization in the US biotechnology sector. Eur Plan Stud 2007;15(6):753-66.
24. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009;8(12):959-68.
25. KesiÄ D. Strategic analysis of the world pharmaceutical industry. Manage J Contemp Manage Issues 2009;14(1):59-76.
26. A K. Drug Quality in Islamic Repulic of Iran. Office for Narcotics and Drug Supervision and Evaluationâ€™s Internal Report; 2001.
27. Rasekh HR, Mehralian G, Vatankhah-Mohammadabadi AA. Situation analysis of R & d activities: an empirical study in Iranian pharmaceutical companies. Iran J Pharm Res 2012;11(4):1013-25.
28. Kenney M. Biotechnology and the Creation of a New Economic Space. Private Science: Biotechnology and the Rise of the Molecular Sciences. Philadelphia, PA: University of Pennsylvania Press; 1998. p. 131-43.
29. Mehralian G, Rajabzadeh A, Sadeh MR, Rasekh HR. Intellectual capital and corporate performance in Iranian pharmaceutical industry. J Intellect Cap 2012;13(1):138-58.
30. 2013. Available from: http://www.scimagojr.com/countrysearch.php?country=IR&area=0. [Last cited on 2013 Dec 4].
31. Subramanian R, Toney JH, Jayachandran C. The evolution of research and development in the pharmaceutical industry: Toward the open innovation modelâ€“can pharma reinvent itself? Int J Bus Innov Res 2011;5(1):63-74.
32. Kebriaizade A, Abdollahiasl A. Take a look at Iran pharmaceutical industry in Iran. Iran J Pharm Res (IJPR);2003; ISSN 1735-031, 9.
33. Descriptive Progress Report. Ministry of Health, Organization FaD; 2005.
34. The Global use of Medicines Outlook Through 2016Report. IMS Institute; 2012.
35. Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy 2000;51(3):149-62.
36. Bae JP. Drug patent expirations and the speed of generic entry. Health Serv Res 1997;32(1):87-101.
37. Pharmaceutical Executive, Strategies for Emerging Markets: Seven Keys to the Kingdom. IMS Health 2010 by Villiam Looney Pharmaceutical executive.
38. Attridge CJ, Preker AS. Improving Access to Medicines in Developing Countries: Application of New Institutional Economics to the Analysis of Manufacturing and Distribution Issues World Bank. Washangton, DC: The World Bank; 2005.
39. Iranian Parliament. National Health Insurance Act. J Med Serv Insur Organ 1994;7:68-71.
40. Mehralian G, Rasekh HR, Akhavan P, Ghatari AR. Prioritization of intellectual capital indicators in knowledge-based industries: Evidence from pharmaceutical industry. Int J Inf Manage 2013;33(1):209-16.